Rifampicin-associated pseudomembranous colitis.
We report a case of pseudomembranous colitis that developed in a patient with liver cirrhosis during anti-tuberculosis therapy with rifampicin and isoniazid. The association between rifampicin and pseudomembranous colitis has been controversial; this report, however, supports the association. Colonoscopy performed 3 days after the onset of the pseudomembranous colitis revealed only reddish patches and a few aphthoid lesions, but 4 days later pseudomembranes were apparent. The pseudomembranous colitis was successfully controlled by discontinuation of the anti-tuberculosis agents, along with the administration of lactic acid bacteria, without vancomycin or metronidazole. Possible predisposing factors for the development of pseudomembranous colitis in this patient are also discussed.
Nakajima
A
A
Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
Yajima
S
S
Shirakura
T
T
Ito
T
T
Kataoka
Y
Y
Ueda
K
K
Nagoshi
D
D
Kanemoto
H
H
Matsuhashi
N
N
D000904:Antibiotics, Antitubercular / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D003113:Colonoscopy; D020345:Enterocolitis, Necrotizing / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D008875:Middle Aged; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000904:Antibiotics, Antitubercular; D012293:Rifampin